Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

NCT ID: NCT06430827

Last Updated: 2024-05-28

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-06-30
• Study Completion Date: 2025-12-31

Brief Summary

To evaluate the efficacy and safety of irinotecan hydrochloride liposome injection combined with Capecitabine for second-line treatment in Patients With advanced or metastatic biliary tract carcinoma.

Conditions

Biliary Tract Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental

Patients will receive irinotecan hydrochloride liposome injection combined with Capecitabine therapy in a 2-week treatment cycle.

Group Type: EXPERIMENTAL

irinotecan hydrochloride liposome injection

Intervention Type: DRUG

rinotecan hydrochloride liposome injection (70mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.

Capecitabine

Intervention Type: DRUG

Capecitabine (1000 mg/m\^2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle

Interventions

irinotecan hydrochloride liposome injection

rinotecan hydrochloride liposome injection (70mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.

Intervention Type: DRUG

Capecitabine

Capecitabine (1000 mg/m\^2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle

Intervention Type: DRUG

Other Intervention Names

duoenyi; Kapeitabin

Eligibility Criteria

Inclusion Criteria

1. The patient had good compliance, could understand the research process of this study, and signed a written informed consent.

2. Age ≥18 years.

3. Has histologically confirmed diagnosis of advanced (metastatic) and/or unresectable (locally advanced) biliary tract cancer (intra-or extrahepatic cholangiocarcinoma or gallbladder cancer).

4. Subjects who had received gemcitabine prior first-line therapy and had not received fluorouracil drugs.

5. Subjects who have progressed after receiving previous first-line therapy, relapse within 6 months after the end of (neo) adjuvant therapy is considered as first-line therapy failure.

6. Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

7. ECOG (Eastern Cooperative Oncology Group) performance status of 0-2.

8. Has a life expectancy of greater than 3 months.

9. LVEF≥50%.

10. Appropriate organ function is defined as follows: (Hematology and blood biochemistry tests must be completed within 14 days prior to enrollment, and the following criteria are met):

1. ANC ≥1.5×10^9/L

2. Hb≥90g/L

3. PLT ≥100×10^9/L

4. total bilirubin ≤1.5 x ULN

5. ALT/AST ≤ 2.5 x ULN; When there is liver metastasis, ALT/AST ≤ 5 x ULN

6. Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CCr) ≥50mL/min (according to Cockcroft-Gault fórmula)

7. Coagulation function: prothrombin time (PT), activated partial thromboplastin time (APTT) and international standardized ratio (INR) ≤1.5×ULN

11. Patients with biliary obstruction should receive adequate biliary drainage.

12. Adverse reactions caused by previous treatment must be restored to grade 1 or baseline according to CTCAE5.0 (except for toxicity such as alopecias, grade 2 and below peripheral neuropathy, which can be included after the investigator determines that there is no safety risk).

13. non-pregnant or lactating female; Effective contraception should be used by female/Male of childbearing age during the study period and for 6 months after the end of study treatment.

14. There were no contraindications for the use of irinotecan liposomes and capecitabine.

Exclusion Criteria

1. Patients who have had other malignant tumors within the previous 5 years (except cured carcinoma in situ and skin basal cell carcinoma).

2. Uncontrolled pleural effusion or ascites.

3. Any known brain or meningeal metastases.

4. Subjects were co-administering a potent CYP3A4 inducer within 3 weeks prior to first dosing, or a potent CYP3A4 inhibitor or a potent UGT1A1 inhibitor within 3 weeks prior to first dosing.

5. Subjects underwent large organ surgery (except needle biopsy, central venous catheterization, port catheterization, stenting for relief of biliary obstruction, percutaneous hepatobiliary drainage, and cholecystostomy) or an elective surgical program within 4 weeks before the first dose of the study drug.

6. Active, uncontrolled bacterial, viral, or fungal infections with systemic treatment, defined as persistent signs/symptoms associated with infection that do not go away despite the use of appropriate antibiotics, antiviral therapy, and/or other treatment, including patients with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).

7. Patients who are known to have dihydropyridine dehydrogenase (low activity) or deficiency.

8. There are serious concomitant diseases: such as uncontrolled diabetes after hypoglycemic drug treatment, uncontrolled hypertension, serious cardiovascular and cerebrovascular disease, kidney failure, liver failure, uncontrolled epilepsy, central nervous system disease or mental disorder history, clear gastrointestinal bleeding tendency, intestinal paralysis, intestinal obstruction, etc.

9. Grade 1 diarrhea with an increase in the number of stools > 4 times per day compared to baseline; The moderate and severe effluents from stoma increased; Limited activities of daily living with the aid of tools or even self-rational activities of daily living; Life-threatening; Need urgent medical attention.

10. Had participated in other clinical investigators within 4 weeks before enrollment.

11. Unsuitable for participation in the trial by the investigator assessed.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Ba Yi

OTHER

Sponsor Role: lead

Responsible Party

Ba Yi

Director

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Yi Ba

Role: PRINCIPAL_INVESTIGATOR

PEKING UNION MEDICALCOLLEGE HOSPITAL

Locations

Peking Union Medicalcollege Hospital

Beijing, , China

Countries

China

Central Contacts

Yi Ba, PHD

Role: CONTACT

bayipumch@aliyun.com

+86 010 69158705

Facility Contacts

Yi Ba, PHD

Role: primary

bayipumch@aliyun.com

+86 010 69158705

Other Identifiers

CSPC-DNY-BTC-02

Identifier Type: -

Identifier Source: org_study_id